Variant Burkitt-type translocation (8;22)(q24;q11) in plasma cell myeloma.
10.5045/kjh.2011.46.2.135
- Author:
Hanah KIM
1
;
Hee Won MOON
;
Mina HUR
;
Yeo Min YUN
;
Chul Min PARK
;
Mark Hong LEE
Author Information
1. Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea. dearmina@hanmail.net
- Publication Type:Case Report
- Keywords:
Plasma cell myeloma;
t(8;
22)(q24;
q11);
Variant;
Burkitt
- MeSH:
Bone Marrow Examination;
Cytogenetic Analysis;
Dexamethasone;
Humans;
Immunoglobulin G;
Male;
Middle Aged;
Multiple Myeloma;
Paraproteinemias;
Pelvic Pain;
Plasma;
Plasma Cells;
Prognosis;
Thalidomide
- From:Korean Journal of Hematology
2011;46(2):135-138
- CountryRepublic of Korea
- Language:English
-
Abstract:
Variant Burkitt-type translocation, t(8;22)(q24;q11), is very rare in plasma cell myeloma. We report a 51-year-old male patient with plasma cell myeloma, who showed t(8;22) (q24;q11). He suffered from pelvic pain for two months, and showed IgG, lambda type of monoclonal gammopathy (5.14 g/dL; 49.9% of protein). His bone marrow examination showed increased plasma cells (66.9% of all nucleated cells). Plasma cells (74.9% of all nucleated cells) and monoclonal spike (3.38 g/dL; 42.2%) persisted after three cycles of thalidomide and dexamethasone. Cytogenetic analysis showed complex chromosomal abnormalities: 44,XY,-1,t(2;5)(q33;q13),add(8)(q24.1),t(8;22)(q24.1;q11.2),add(10) (p15), der(11)t(1;11)(q21;p11.2),del(12)(p11.2p13),-13,-14,add(14)(q32),der(15)t(1;15)(p2 2;p11.2),-16,add(17)(q11.2),+21,+1-3mar[cp6]/46,XY[19]. To the best of our knowledge, this is the first report on plasma cell myeloma with a variant Burkitt-type t(8;22)(q24;q11) in the Korean patient. A review of 11 such cases in the literature, including the present case, implicated that plasma cell myeloma with t(8;22)(q24;q11) might be related to advanced stage and poor prognosis.
